Who Pays My Doctor?

Healthcare provider profile · identity verified

David Jacob Scheiderer, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ROANOKE, VA · NPI 1699978221

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David Jacob Scheiderer, M.D. received $508,360.17 in general payments during 2025 across 403 reported records.

ABBVIE INC. accounted for 27.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 9 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$508,360.17

403 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $138,253.5627.2%1072025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $128,466.6925.3%972025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $117,587.6023.1%892025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $97,919.2119.3%862025
Alkermes, Inc. Unresolved — no canonical attribution shown $23,093.664.5%212025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $2,940.000.6%12025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $69.120.0%12025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $30.330.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$323,869.5091
Honoraria$115,919.0033
Travel and Lodging$47,901.54146
Consulting Fee$11,696.254
Food and Beverage$8,973.88129

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $136,498.56 106 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $120,997.57 94 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $117,587.60 89 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc. $97,919.21 86 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $23,093.66 21 2025
Source payment records
Sunosi
Normalized: sunosi		 Drug Axsome Therapeutics, Inc. $7,469.12 3 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $2,940.00 1 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $30.33 1 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $25.44 2 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
CAPLYTA
caplyta		 2025 Caplyta 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
OlanzapineOlanzapine25suppressed
Fluoxetine HclFluoxetine Hcl14suppressed
LamotrigineLamotrigine13suppressed
CaplytaLumateperone Tosylate12suppressed
ClozapineClozapine12suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $508,360.17 · 403 records ABBVIE INC. ARISTADA, Auvelity, CAPLYTA, FANAPT, INGREZZA, LYBALVI, REXULTI, Sunosi, VRAYLAR 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error